Enliven Therapeutics (NASDAQ:ELVN) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Enliven Therapeutics (NASDAQ:ELVN) released its earnings results on Thursday. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07, Zacks reports.

Enliven Therapeutics Price Performance

ELVN traded down $0.73 during trading on Thursday, hitting $20.29. 141,655 shares of the stock traded hands, compared to its average volume of 231,401. The firm has a market capitalization of $991.35 million, a P/E ratio of -10.68 and a beta of 1.04. The firm has a 50-day moving average of $21.73 and a 200 day moving average of $23.84. Enliven Therapeutics has a 12-month low of $10.90 and a 12-month high of $30.03.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $25.04, for a total value of $25,040.00. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $325,520. This represents a 7.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 21,700 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The disclosure for this sale can be found here. Insiders sold 47,784 shares of company stock valued at $1,092,375 in the last quarter. Company insiders own 29.20% of the company’s stock.

Wall Street Analyst Weigh In

ELVN has been the topic of several recent research reports. BTIG Research initiated coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 target price on the stock. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.